OLMESARTAN MEDOXOMIL 40mg. IP + AMLODIPINE 5mg. IP + HYDROCHLOROTHIAZIDE 12.5mg....

A triple antihypertensive therapy for patients whose BP was inadequately controlled with monotherapy or require multiple medications. (Mustafa Abrar Zaman, 2023) A promising triple combination drug therapy for managing high-risk hypertension. (Mustafa Abrar Zaman, 2023) A well-tolerated and efficacious drug in individuals with moderate-to-severe hypertension, including those with cardiovascular disease, chronic kidney disease, and diabetes mellitus. (Peter Bramlage, 2015) Enhances treatment adherence and contributes to improved patient outcomes compared to multiple separate tablets. (Peter Bramlage, 2015) Demonstrates effectiveness and safety in achieving blood pressure (BP) control among obese patients with hypertension who were uncontrolled on monotherapy. (Willa A Hsueh, 2012) Promotes the excretion of sodium and water, reduces blood volume, and consequently lowers blood pressure. A viable option for managing hypertension in obese patients who require combination therapy due to inadequate response to monotherapy. (Willa A Hsueh, 2012) An effective, well-tolerated, and convenient approach aiding patients in achieving blood pressure control. (Benjamin J Epstein, 2013)